Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry

Geert D'Haens, Walter Reinisch, Remo Panaccione, Jack Satsangi, Joel Petersson, Mareike Bereswill, Dilek Arikan, Eva Perotti, Anne M. Robinson, Jasmina Kalabic, Gabriela Alperovich, Roopal Thakkar, Edward V. Loftus

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry'. Together they form a unique fingerprint.

Medicine & Life Sciences